These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 27837610)
1. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma. Baliou E; Nonni A; Keramopoulos D; Ragos V; Tsiambas E; Patsouris E; Pavlakis K J BUON; 2016; 21(5):1099-1103. PubMed ID: 27837610 [TBL] [Abstract][Full Text] [Related]
2. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108 [TBL] [Abstract][Full Text] [Related]
3. Expression profile of tumour suppressor protein p53 and its regulator MDM2 in a cohort of breast cancer patients in a Tertiary Hospital in Ghana. Opoku F; Bedu-Addo K; Titiloye NA; Atta Manu E; Ameh-Mensah C; Duduyemi BM PLoS One; 2021; 16(10):e0258543. PubMed ID: 34695137 [TBL] [Abstract][Full Text] [Related]
4. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823 [TBL] [Abstract][Full Text] [Related]
6. bcl-2 expression in the spectrum of preinvasive breast lesions. Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957 [TBL] [Abstract][Full Text] [Related]
8. [Interaction between p53 and MDM2 in human lung cancer cells]. Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Gatalica Z Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of Mdm2 and p53 in feline mammary gland tumors. Nakano M; Wu H; Taura Y; Inoue M J Vet Med Sci; 2006 May; 68(5):421-5. PubMed ID: 16757883 [TBL] [Abstract][Full Text] [Related]
11. P53/MDM2 Co-Expression in Laryngeal Squamous Cell Carcinoma Based on Digital Image Analysis. Chrysovergis A; Papanikolaou V; Tsiambas E; Stavraka C; Ragos V; Peschos D; Psyrri A; Mastronikolis N; Kyrodimos E Anticancer Res; 2019 Aug; 39(8):4137-4142. PubMed ID: 31366498 [TBL] [Abstract][Full Text] [Related]
12. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938 [TBL] [Abstract][Full Text] [Related]
13. p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Rajan PB; Scott DJ; Perry RH; Griffith CD Breast Cancer Res Treat; 1997 Feb; 42(3):283-90. PubMed ID: 9065612 [TBL] [Abstract][Full Text] [Related]
14. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361 [TBL] [Abstract][Full Text] [Related]
15. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas. Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188 [TBL] [Abstract][Full Text] [Related]
16. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511 [TBL] [Abstract][Full Text] [Related]
17. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas. Gursan N; Karakök M; Sari I; Gursan MS Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353 [TBL] [Abstract][Full Text] [Related]
18. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function. Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313 [TBL] [Abstract][Full Text] [Related]
19. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370 [TBL] [Abstract][Full Text] [Related]
20. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]